Publications by authors named "R van den Hoven"
Rhodococcus equi (R. equi) is a primary cause of pyogranulomatous pneumonia of foals between three weeks and five months of age. Early diagnosis of rhodococcal pneumonia has always been considered a preferable approach as it can lead to more successful treatment and better outcomes.
View Article and Find Full Text PDFMore than half of chronic rhinosinusitis with nasal polyps (CRSwNP) patients treated with dupilumab experience early and fast olfactory improvement within 28 days.
Allergy
November 2024
The data on the number of animals used for experimental purposes, with a particular focus on regulatory toxicity studies, in Turkey and EU member states plus Norway (EU+), were compared for the period 2015 to 2020 (UK data after Brexit for 2020 were included too). The total number of listed vertebrates used for regulatory toxicity testing in the full 6-year reporting period in Turkey was 3.6% of that reported for the EU+.
View Article and Find Full Text PDFArticle Synopsis
- Rhodococcus equi (R. equi) is a significant pneumonia-causing pathogen in foals, often leading to severe health issues and deaths.
- A study aimed to analyze changes in various blood components and immune markers in foals undergoing treatment with azithromycin-rifampicin over 14 days.
- Results showed a notable decrease in white blood cell counts, neutrophils, monocytes, and fibrinogen levels, along with increased IL-2 and IL-10 concentrations, suggesting that monitoring certain cytokines could provide insights into the immune response during R. equi pneumonia treatment.
Background: There is no known predictor for olfactory function recovery with dupilumab treatment in chronic rhinosinusitis with nasal polyps (CRSwNP). This study assessed whether patient-reported recovery of olfactory function on oral corticosteroids (OCS) is a prognostic factor.
Methods: Retrospective analysis of pre-biological OCS-responsiveness on olfactory functioning (OCS-responsive or OCS-unresponsive; OCS-r and OCR-u, respectively) as predictor for olfactory functioning after 6 months of dupilumab therapy for severe CRSwNP.